AbbVie: Fundamental Disconnect [Seeking Alpha]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Seeking Alpha
Summary AbbVie Synopsis The performance of AbbVie ( ABBV ) shares through 2018 can be characterized as lackluster. It has performed similar to the S&P 500 and is just above break-even at .8% return on the year. A lot of pessimism is built into the share price relating to two failed clinical tests by Rova T and Imbruvica. The stock market is beginning to question AbbVie’s pipeline of 20 drugs and its ability to supplement the massive growth in sales of its Humira drug line. Humira has been a massive success. It is an extremely profitable drug for AbbVie and it accounts for over 66% of its net revenue ($18.4 billion). The company secured a deal with Samsung Bioepis and partner Biogen (NASDAQ: BIIB ) to fend off generics until 2022. It has been developing immunotherapy cancer drugs and is reliant on research and development to internally develop a Humira replacement which will decrease its reliance and revenue concentration risk. Its second top-selling drug is called Imbru
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake [Yahoo! Finance]Yahoo! Finance
- Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $294.00 price target on the stock.MarketBeat
- Should You Be Confident in Biogen (BIIB)? [Yahoo! Finance]Yahoo! Finance
- What's in Store for Biogen (BIIB) This Earnings Season? [Yahoo! Finance]Yahoo! Finance
BIIB
Earnings
- 4/24/24 - Beat
BIIB
Sec Filings
- 4/24/24 - Form 10-Q
- 4/24/24 - Form 8-K
- 4/12/24 - Form PRE
- BIIB's page on the SEC website